Effekterna av opiodsparande, personcentrerade vårdvägar för patienter som genomgår obesitas kirurgi | Application
Effekterna av opiodsparande, personcentrerade vårdvägar för patienter som genomgår obesitas kirurgi
Registration number: ALFGBG-815051
2018 Ansökan ALF-projektmedel med tilldelning 2019-2020
Application started by: Axel Wolf, 2018-05-02
Professional title at the time of application: Universitetslektor/Översjuksköterska
Work place at the time of application: Sahlgrenska Universitetssjukhuset/Östra Område 2 AnOpIva + Institutionen för Vårdvetenskap och Hälsa
Last updated / corrected by: Axel Wolf, 2018-06-03
Application received by: ALF-medel Västra Götalandsregionen
GrantedGranted
Applicant: Axel Wolf
Universitetslektor/Översjuksköterska, An/Op/Iva Östra, Institutionen för vårdvetenskap och hälsa

Övergripande projektinformation

Projektsammanfattning svenska eller engelska

Up to 30% of patients that undergo obesity surgery (gastric by-pass GBP or Sleeve) seek hospital care within 3 years, and 50% have abdominal pain. Studies have shown that GBP patients have an increased intake of opioids from the intestine, increasing the risk of chronic opioid usage, and prolonged opioid usage lead to paradoxically increasing pain. Opioids today are standard treatments for acute postoperative pain and often provide good pain relief, nevertheless, opioids have side effects such as respiratory distress, bladder/bowel dysfunction, sedation and nausea. The globally increased prescription of opioids is an increasing problem.

We lack the knowledge of the effects of opioid-free pharmacological, none-pharmacological and person-centred strategies aiming to reduce/eliminating the need for opioids for patients undergoing obesity surgery. The patient population is expected to be an increasing part of the surgical volume, hence innovative solutions that can optimize care and outcomes are needed.

The study will evaluate the effects of an opioid-sparing care pathway in comparison with conventional opioid treatment regarding pain, opioid consumption, post-operative recovery and self-efficacy up to 24 months after obesity surgery. Quantitative and qualitative methods will be used in this randomized, non-blinded, noncommercial single site study (Nov 2018-Dec 2022), approved by the Swedish Medicines Agency (EudraCT 2017003830-97) and the ethical review board (DNR 1006-17).

Decision

Decision date: 2018-11-08

Decision 
Applied sum1,868,900
Granted sum500,000

Effekterna av opiodsparande, personcentrerade vårdvägar för patienter som genomgår obesitas kirurgi | Application, from ALF-medel Västra Götalandsregionen
http://www.researchweb.org/is/alfgbg/ansokan/815051